New classification of moricizine and propafenone based on electrophysiologic and electrocardiographic data from isolated rabbit heart.
Because the classification of propafenone and moricizine is not clear, we measured in 20 specifically equipped isolated rabbit hearts QRS duration, QT interval, action potential duration at 90% of repolarization (APD90), effective refractory period (ERP), conduction time (CT), and rise velocity (Rv) of the monophasic action potentials (AP) during exposure to moricizine and propafenone in comparison with procainamide. Propafenone and procainamide prolonged APD90 and JT. All drugs increased ERP. Propafenone demonstrated marked tonic sodium channel block. Onset of use-dependent kinetics (tau on), defined as change in Rv as fraction per beat at 300 ms cycle length (CL), were 0.047 +/- 0.004/beat for procainamide, 0.050 +/- 0.004/beat for propafenone, and 0.022 +/- 0.003/beat for miricizine. Recovery kinetics, defined as recovery of Rv after cessation of pacing, had a time constant of 5.3 +/- 0.7 s for procainamide, 6.3 +/- 0.8 s for propafenone, and 25.0 +/- 1.3 s for moricizine. Based on these data, moricizine must be classified as a Ic agent, whereas propafenone demonstrates pronounced tonic sodium channel block, in addition to its phasic block, which is similar to class Ia kinetics.
Koller
B
B
Pharmacology Department, Georgetown University, Washington, D.C.
Franz
M R
MR
D000200:Action Potentials / Q000187:drug effects; D000704:Analysis of Variance; D000818:Animals; D004562:Electrocardiography / Q000187:drug effects; D004594:Electrophysiology; D005260:Female; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D016293:Moricizine / Q000145:classification / Q000494:pharmacology*; D011342:Procainamide / Q000494:pharmacology; D011405:Propafenone / Q000145:classification / Q000494:pharmacology*; D011817:Rabbits; D026941:Sodium Channel Blockers
D026941:Sodium Channel Blockers; D016293:Moricizine; D011405:Propafenone; D011342:Procainamide